The concern with AbbVie’s blockbuster biologic Humira is the lost of patent exclusivity in the U.S. and Europe over the next two years. The worry is revenue from Humira will drop off a cliff as generic drugs enter the market…. Read More
Starbucks’ Float
It’s Christmas time. A good time for Starbucks. Not because they will sell more hot drinks. They will. It’s because of all those Starbucks gift cards given out. You know you will receive at least one. Any funds loaded onto… Read More